The cognitive symptoms of schizophrenia are largely resistant to current treatment and are
thus a life-long burden of the illness. Studies of cognitive symptoms have commonly focused …

Emerging evidence points to the involvement of the brain extracellular matrix (ECM) in the
pathophysiology of schizophrenia (SZ). Abnormalities affecting several ECM components …

We present a DNA library preparation method that has allowed us to reconstruct a high-
coverage (30×) genome sequence of a Denisovan, an extinct relative of Neandertals. The …

An association between a catechol-O-methyltransferase (COMT) Val156Met (rs4680)
polymorphism and schizophrenia has been reported in the literature, although no conclusive …

Antipsychotic drugs targeting dopamine neurotransmission are still the principal mean of
therapeutic intervention for schizophrenia. However, about one third of people do not …

DTNBP1 (dystrobrevin binding protein 1) is a leading candidate susceptibility gene in
schizophrenia and is associated with working memory capacity in normal subjects. In …

The role of dopamine D2 receptor (DRD2) polymorphisms in schizophrenia remains
controversial. We performed a meta‐analysis to determine whether DRD2 polymorphisms …

Background Single nucleotide polymorphism (SNP) variants are abundant, persistent and
widely distributed across the genome and are frequently linked to the development of …

Background The association between the dopamine D2 receptor (DRD2) gene and
schizophrenia has been studied though no conclusive outcomes have been attained. The …

Background Cognitive deficits such as poor selective attention and executive functions
decline have been reported in patients with schizophrenia. Many studies have emphasized …